U.S. markets close in 3 hours 46 minutes
  • S&P 500

    +24.76 (+0.72%)
  • Dow 30

    +185.24 (+0.66%)
  • Nasdaq

    +68.42 (+0.60%)
  • Russell 2000

    +14.17 (+0.88%)
  • Crude Oil

    -0.04 (-0.10%)
  • Gold

    +2.70 (+0.14%)
  • Silver

    +0.20 (+0.82%)

    +0.0059 (+0.50%)
  • 10-Yr Bond

    +0.0150 (+1.97%)

    +0.0010 (+0.08%)

    +0.1470 (+0.14%)

    +913.95 (+8.27%)
  • CMC Crypto 200

    +2.16 (+0.90%)
  • FTSE 100

    +4.57 (+0.08%)
  • Nikkei 225

    -104.09 (-0.44%)

October FDA, CDC Meetings On Coronavirus Vaccines Set Stage For Emergency Use Authorization

Shanthi Rexaline
·3 mins read

Even as the world — and investors — await a coronavirus vaccine, the timeline has become increasingly hard to gauge given clinical setbacks and the risks inherent with fast development. 

An analyst at Canaccord Genuity said a year-end timeline looks a possibility, going by two key events scheduled for this month. 

Upcoming FDA, CDC Meetings: With five SARS-CoV-2 vaccine candidates in pivotal Phase 3 trials, two meetings scheduled for late October could be the key, Canaccord analyst Arlinda Lee said in a note. 

The FDA's Vaccines and Related Biological Products Advisory Committee is scheduled to meet between 10 a.m. and 5 p.m. on Oct. 22 to discuss the development, authorization and/or licensure of vaccines to prevent COVID-19.

Also on tap is the CDC's Advisory Committee on Immunization Practices meeting. The AICP panel will meet Oct. 28-30, which is one of its customary three yearly meetings to review scientific data and vote on vaccine recommendations.

Related Link: Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates

The Late-Stage Coronavirus Vaccine Programs: AstraZeneca plc's (NASDAQ: AZN) ChAdOx1 nCoV-19, a chimpanzee adenovirus expressing SARS-CoV-2 spike, is in late-stage trials in the U.K., India and South Africa.

The late-stage study in the U.K. was voluntarily paused briefly due to an adverse event in one of the study participants.

The U.S. leg of the study remains halted, with a Reuters report suggesting the FDA has widened the scope of its probe into the halted trial.

Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR (NASDAQ: BNTX), which are collaborating on a mRNA vaccine against SARS-CoV-2, recently amended its Phase 3 study protocol to increase the targeted enrollment from 30,000 to 44,000.

The increase was to accommodate a diverse population.

Recently, BioNTech announced plans to acquire Novartis AG's (NYSE: NVS) GMP-certified manufacturing facility in Germany, which would increase its COVID-19 vaccine production capacity by up to 750 million doses per year.

Johnson & Johnson (NYSE: JNJ) initiated a Phase 3 study of its coronavirus vaccine candidate JNJ-78436735 on Sept. 23.

JNJ-78436735 is manufactured using J&J's AdVac technology platform, which was used to develop and manufacture its Janssen unit's European Commission-approved Ebola vaccine.

The company has an early 2021 timeline for emergency use authorization. 

Moderna Inc (NASDAQ: MRNA) has enrolled over 90% of the targeted enrollment number of 30,000 in the Phase 3 trial of its vaccine candidate mRNA-1273. The company is guiding for emergency use authorization by the end of 2020, although it doesn't expect authorization to come before the end of November.

Novavax, Inc. (NASDAQ: NVAX) has an ongoing Phase 3 study of its NVX-CoV2373, a recombinant nanoparticle vaccine, in the U.K.

The company plans to start a late-stage study in the U.S. in October.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.